Patient no. | Sex | Age at diagnosis (y) | WHO grade | ECOG performance status | Resection at primary operation* | Primary RT/TMZ therapy | TMZ series | Best response | Corticosteroids at start of RT/TMZ | Bevacizumab/irinotecan | Reoperation | uPAR mRNA expression |
1† | F | 53 | IV | — | — | — | — | — | — | — | — | 4.57 |
2† | M | 40 | IV | 0 | Partial | Yes | 0 | PD | Yes | No | Yes | 20.62 |
3 | M | 40 | IV | 0 | Gross total | Yes | 1 | PD | Yes | Yes | Yes | 1.54 |
4† | M | 63 | IV | 2 | Gross total | Yes | 1 | PD | Yes | No | No | 4.71 |
5 | M | 63 | IV | 0 | Partial | Yes | 5 | SD | Yes | Yes | No | 1.88 |
6 | F | 34 | IV | 0 | Gross total | Yes | 6 | SD | No | Yes | No | 0.35 |
7 | M | 59 | IV | 0 | Gross total | Yes | 5 | SD | Yes | Yes | Yes | 2.49 |
8 | M | 40 | IV | 0 | Gross total | Yes | 0 | PD | Yes | Yes | Yes | 2.21 |
9 | F | 54 | IV | 2 | Partial | Yes | 2 | PD | No | No | Yes | 1.23 |
10† | M | 64 | IV | 0 | Gross total | Yes | 5 | PR | No | No | Yes | 6.54 |
11 | F | 58 | IV | 0 | Partial | Yes | 2 | PD | Yes | No | No | 1.06 |
12† | M | 63 | IV | 1 | Partial | Yes | 0 | PD | Yes | No | No | 3.78 |
13 | F | 60 | IV | 0 | Gross total | Yes | 2 | PD | Yes | Yes | No | 2.15 |
14 | F | 56 | IV | 0 | Partial | Yes | 5 | SD | Yes | Yes | Yes | 2.39 |
15 | M | 64 | IV | 0 | Partial | Yes | 6 | PR | No | Yes | Yes | 2.04 |
16† | F | 67 | IV | 1 | Gross total | Yes | 3 | SD | Yes | No | Yes | 4.75 |
17† | F | 61 | IV | 0 | Gross total | Yes | 2 | PD | Yes | Yes | No | 14.41 |
18 | M | 47 | IV | 0 | Gross total | Yes | 2 | PD | No | Yes | Yes | 1.63 |
19†‡ | F | 54 | IV | 0 | Partial | Yes | 2 | PD | Yes | Yes | No | 5.63 |